Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126


Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.

Park AL, Lin HK, Yang Q, Sing CW, Fan M, Mapstone TB, Gross NL, Gumerlock MK, Martin MD, Rabb CH, Fung KM.

Int J Clin Exp Pathol. 2010 Mar 25;3(8):743-54.


Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.

Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JV, Culkin DJ, Kropp BP, Penning TM, Lin HK.

Endocr Relat Cancer. 2006 Mar;13(1):169-80.


Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.

Azzarello J, Fung KM, Lin HK.

J Histochem Cytochem. 2008 Sep;56(9):853-61. doi: 10.1369/jhc.2008.951384. Epub 2008 Jun 23.


Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.

Byrns MC, Duan L, Lee SH, Blair IA, Penning TM.

J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):177-87. doi: 10.1016/j.jsbmb.2009.12.009. Epub 2009 Dec 28.


Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.

Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM, Fung KM.

Int J Clin Exp Pathol. 2010 Jul 5;3(6):608-17.


Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.

Azzarello JT, Lin HK, Gherezghiher A, Zakharov V, Yu Z, Kropp BP, Culkin DJ, Penning TM, Fung KM.

Int J Clin Exp Pathol. 2009 Nov 15;3(2):147-55.


Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.

Miller VL, Lin HK, Murugan P, Fan M, Penning TM, Brame LS, Yang Q, Fung KM.

Int J Clin Exp Pathol. 2012;5(4):278-89. Epub 2012 Apr 26.


Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.

Hevir N, Vouk K, Sinkovec J, Ribič-Pucelj M, Rižner TL.

Chem Biol Interact. 2011 May 30;191(1-3):217-26. doi: 10.1016/j.cbi.2011.01.003. Epub 2011 Jan 11.


Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.

Xie L, Yu J, Guo W, Wei L, Liu Y, Wang X, Song X.

Cancer Gene Ther. 2013 Apr;20(4):260-6. doi: 10.1038/cgt.2013.15. Epub 2013 Mar 22.


Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.

Chang TS, Lin HK, Rogers KA, Brame LS, Yeh MM, Yang Q, Fung KM.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2419-29. eCollection 2013.


Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).

Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore M, Ratnam K, Palackal N.

Mol Cell Endocrinol. 2001 Jan 22;171(1-2):137-49.


Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.

Lin SX, Shi R, Qiu W, Azzi A, Zhu DW, Dabbagh HA, Zhou M.

Mol Cell Endocrinol. 2006 Mar 27;248(1-2):38-46. Epub 2006 Feb 15. Review.


Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.

Byrns MC, Penning TM.

Chem Biol Interact. 2009 Mar 16;178(1-3):221-7. doi: 10.1016/j.cbi.2008.10.024. Epub 2008 Nov 1.


Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.

Byrns MC, Jin Y, Penning TM.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):95-104. doi: 10.1016/j.jsbmb.2010.11.004. Epub 2010 Nov 16. Review.


AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.

Skarydová L, Zivná L, Xiong G, Maser E, Wsól V.

Chem Biol Interact. 2009 Mar 16;178(1-3):138-44. doi: 10.1016/j.cbi.2008.10.015. Epub 2008 Oct 19.


Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.

Mantel A, Carpenter-Mendini A, VanBuskirk J, Pentland AP.

Exp Dermatol. 2014 Aug;23(8):573-8. doi: 10.1111/exd.12468. Epub 2014 Jul 16.

Supplemental Content

Support Center